6 Einträge gefunden

1. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3

   1. Reich, K
   2. Iversen, L
   3. Puig, L
   4. Lambert, J
   5. Mrowietz, U
   6. Kaplan Saday, K
   7. Warren, R B

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3

   1. Reich, K
   2. Hansen, J B
   3. Puig, L
   4. Konstantinou, M P
   5. Warren, R B

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

   1. Warren, R B
   2. Hansen, J B
   3. Reich, K
   4. Paul, C
   5. Puig, L

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study

   1. Reich, K
   2. Puig, L
   3. Szepietowski, J C
   4. Paul, C
   5. Lacour, J P
   6. Tsianakas, A
   7. Sieder, C

   2020 - Forschungsinformationssystem des UKE
5. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

   1. Reich, K
   2. Warren, R B
   3. Iversen, L
   4. Puig, L
   5. Pau-Charles, I
   6. Igarashi, A
   7. Ohtsuki, M

   2020 - Forschungsinformationssystem des UKE
6. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

   1. Reich, K
   2. Puig, L
   3. Paul, C
   4. Kragballe, K
   5. Luger, T
   6. Lambert, J
   7. Chimenti, S

   2014 - Forschungsinformationssystem des UKE